Literature DB >> 26869588

The benefit of surgical resection in recurrent glioblastoma.

Michael A Vogelbaum1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26869588      PMCID： PMC4799689          DOI： 10.1093/neuonc/now004

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  13 in total

Review 1.  Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors.

Authors:  R Sawaya; M Hammoud; D Schoppa; K R Hess; S Z Wu; W M Shi; D M Wildrick
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

2.  Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.

Authors:  G Evren Keles; Edward F Chang; Kathleen R Lamborn; Tarik Tihan; Chih-Ju Chang; Susan M Chang; Mitchel S Berger
Journal:  J Neurosurg       Date:  2006-07       Impact factor: 5.115

3.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial.

Authors:  Walter Stummer; Uwe Pichlmeier; Thomas Meinel; Otmar Dieter Wiestler; Friedhelm Zanella; Hans-Jürgen Reulen
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

4.  Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; D F Nelson; A J Fischbach; C H Chang; M Rotman; S O Asbell
Journal:  J Neurooncol       Date:  1992-03       Impact factor: 4.130

5.  Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial.

Authors:  Christian Senft; Andrea Bink; Kea Franz; Hartmut Vatter; Thomas Gasser; Volker Seifert
Journal:  Lancet Oncol       Date:  2011-08-23       Impact factor: 41.316

6.  An extent of resection threshold for newly diagnosed glioblastomas.

Authors:  Nader Sanai; Mei-Yin Polley; Michael W McDermott; Andrew T Parsa; Mitchel S Berger
Journal:  J Neurosurg       Date:  2011-03-18       Impact factor: 5.115

7.  Use of high-field intraoperative magnetic resonance imaging to enhance the extent of resection of enhancing and nonenhancing gliomas.

Authors:  Alireza Mohammad Mohammadi; T Barrett Sullivan; Gene H Barnett; Violette Recinos; Lilyana Angelov; Kambiz Kamian; Michael A Vogelbaum
Journal:  Neurosurgery       Date:  2014-04       Impact factor: 4.654

8.  Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme.

Authors:  Matthew J McGirt; Debraj Mukherjee; Kaisorn L Chaichana; Khoi D Than; Jon D Weingart; Alfredo Quinones-Hinojosa
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

9.  Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.

Authors:  Matthew M Grabowski; Pablo F Recinos; Amy S Nowacki; Jason L Schroeder; Lilyana Angelov; Gene H Barnett; Michael A Vogelbaum
Journal:  J Neurosurg       Date:  2014-09-05       Impact factor: 5.115

10.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.

Authors:  Jason Beiko; Dima Suki; Kenneth R Hess; Benjamin D Fox; Vincent Cheung; Matthew Cabral; Nicole Shonka; Mark R Gilbert; Raymond Sawaya; Sujit S Prabhu; Jeffrey Weinberg; Frederick F Lang; Kenneth D Aldape; Erik P Sulman; Ganesh Rao; Ian E McCutcheon; Daniel P Cahill
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300
View more
  5 in total

1.  Re-irradiation after gross total resection of recurrent glioblastoma : Spatial pattern of recurrence and a review of the literature as a basis for target volume definition.

Authors:  Christoph Straube; Greeshma Elpula; Jens Gempt; Julia Gerhardt; Stefanie Bette; Claus Zimmer; Friederike Schmidt-Graf; Bernhard Meyer; Stephanie E Combs
Journal:  Strahlenther Onkol       Date:  2017-06-14       Impact factor: 3.621

2.  Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.

Authors:  Benjamin M Ellingson; Robert J Harris; Davis C Woodworth; Kevin Leu; Okkar Zaw; Warren P Mason; Solmaz Sahebjam; Lauren E Abrey; Dana T Aftab; Gisela M Schwab; Colin Hessel; Albert Lai; Phioanh L Nghiemphu; Whitney B Pope; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2016-08-31       Impact factor: 12.300

3.  Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival.

Authors:  Jeongshim Lee; Sung Soo Ahn; Jong Hee Chang; Chang Ok Suh
Journal:  Yonsei Med J       Date:  2018-03       Impact factor: 2.759

4.  Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial).

Authors:  Christoph Straube; Hagen Scherb; Jens Gempt; Jan Kirschke; Claus Zimmer; Friederike Schmidt-Graf; Bernhard Meyer; Stephanie E Combs
Journal:  BMC Cancer       Date:  2018-01-03       Impact factor: 4.430

Review 5.  Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 recurrent glioblastoma.

Authors:  Shervin Taslimi; Vincent C Ye; Patrick Y Wen; Gelareh Zadeh
Journal:  Neurooncol Adv       Date:  2021-02-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.